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SUMMARY
Tuberculosis remains a major threat as drug resistance continues to increase. Pulmonary
tuberculosis in adults is responsible for 80% of clinical cases and nearly 100% of transmission of
infection. Unfortunately, since we have no animal models of adult type pulmonary tuberculosis,
the most important type of disease remains largely out of reach of modern science and many
fundamental questions remain unanswered. This paper reviews research dating back to the 1950’s
providing compelling evidence that cord factor (trehalose 6,6′ dimycolate [TDM]) is essential for
understanding tuberculosis. However, the original papers by Bloch and Noll were too far ahead of
their time to have immediate impact. We can now recognize that the physical and biologic
properties of cord factor are unprecedented in science, especially its ability to switch between two
sets of biologic activities with changes in conformation. While TDM remains on organisms, it
protects them from killing within macrophages, reduces antibiotic effectiveness and inhibits the
stimulation of protective immune responses. If it comes off organisms and associates with lipid,
TDM becomes a driver of tissue damage and necrosis. Studies emanating from cord factor
research have produced (1) a rationale for improving vaccines, (2) an approach to new drugs that
overcome natural resistance to antibiotics, (3) models of caseating granulomas that reproduce
multiple manifestations of human tuberculosis. (4) evidence that TDM is a key T cell antigen in
destructive lesions of tuberculosis, and (5) a new understanding of the pathology and pathogenesis
of postprimary tuberculosis that can guide more informative studies of long standing mysteries of
tuberculosis.
Keywords
Tuberculosis; Trehalose dimycolate; Cord factor; Caseating granuloma; Cavity; Drug
1. Introduction
In spite of the best efforts of modern science, M. tuberculosis (MTB) persists throughout the
world and kills more people than any other bacterial infection. Drug resistance continues to
rise. Genetic analysis, molecular biology, combinatorial chemistry and high-throughput
screening have produced no new drugs. Nor have they been able to improve on a vaccine,
BCG, developed in the 1920’s. Similarly, key questions of the disease remain unanswered.
Why can’t immunity control established infection when most infected people never get sick?
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How can MTB be an obligate human parasite when people are more resistant to disease than
most animals? How does MTB damage tissue? How can it grow in vast numbers in one part
of a lung, while the rest of the lung and all other parts of the body remain highly resistant?
These questions remain unanswered because they are seldom addressed since we lack
experimental models and methods to study them.
Scientists since Koch have looked for virulence factors of MTB. A virulence factor is a
component or attribute of an organism that facilitates disease. The oldest, most durable and
best documented virulence factor of MTB is cord formation. Koch noted that virulent MTB
grow in twisted rope-like aggregates known as serpentine cords. Middlebrook wrote that
cord formation was an “essential accompaniment of virulence”.1 Bloch and Noll identified a
lipid, cord factor (trehalose 6,6′ dimycolate [TDM]), on the surface of virulent MTB and
published the following evidence that it is a virulence factor:2–4
1. TDM is the most abundant and most toxic lipid produced by MTB. Since MTB is
an obligate human parasite, it is safe to assume that every component has been
selected to promote its survival in humans.
2. Much more TDM can be extracted from the surface of virulent than avirulent MTB.
3. Removal of TDM from MTB abolishes its ability to produce progressive infection
in mice.
4. Injections of TDM too small to cause toxicity by themselves enhance both acute
and chronic tuberculosis causing mice to die sooner of massive infections. The
effect is specific for tuberculosis.
One might expect the scientific community to vigorously pursue such compelling evidence.
In actuality, the opposite happened. The concept that TDM might be a virulence factor for
MTB was vigorously attacked by the leading scientists of the day, none of whom ever
attempted to repeat the studies.5–7 The concept was denounced as “unphysiologic” because
scientists could neither understand nor study it further with technologies of the day. Bloch
and Noll were too far ahead of their time with a revolutionary new concept of science. As
Kuhn explained, when faced with the choice of adapting to a new idea or proving it wrong,
most people work on the proof.8
2. The toxic surface of TDM – new concept in biology
Our studies began with investigations of surface-active vaccine adjuvants before we learned
the troubled history of TDM.9,10 We became fascinated by the observation that the toxicity
of TDM was due to an extremely rigid insoluble crystalline monolayer that formed
spontaneously at water–hydrophobe interfaces.11 The LD50 of the toxic TDM monolayer
approximates 30 μg/mouse while doses of 50,000 μg of the nontoxic TDM micelles produce
no overt toxicity. We realized that such activity had never been described for any biologic
substance and that TDM did not fit into any know category of toxin. The structure of both
the toxic monolayer and nontoxic micelles of TDM were deduced from physical chemical
studies and confirmed by scanning tunneling microscopy,12,13 Fig. 1. The toxic monolayer
of TDM is the most stable and ridged biologic monolayer ever described. It consists of
linear arrays of trehalose head groups alternating with exposed hydrophobic mycolic acid
domains. This structure forms spontaneously at water–hydrophobe interfaces including oil,
polystyrene and air. The intensity of inflammation induced by the TDM monolayer is a
function of its surface area, but is not otherwise related to dose.14 The surface of the non-
toxic cylindrical micelles of TDM is composed entirely of trehalose head groups. The
extreme insolubility of TDM contributes to the long-term stability of these structures.
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The concept of toxic surfaces is well established for mineral crystals, but had never before
been described for a microbiologic product. SiO2 exists in four crystalline forms. Its toxicity
varies from extreme (tridimyte) to none (stitsovite) depending on the crystal structure.15,16
Quartz has intermediate structure and toxicity. In another example, pure carbon can exist as
graphite that is non toxic or as carbon nanotubes that are very toxic.17 Other examples are
asbestos and monosodium urate. The biologic activity of each of these materials is
dependent on the configuration of atoms on the surface of insoluble crystals.
Over the years, we and others have gradually repeated all of Bloch & Noll’s studies and
learned much more about TDM. Several investigators have studied it as a conventional lipid.
While interesting things have been learned, such studies miss the significance of its surface-
dependent activities. We proposed that TDM is ‘the key’ to understanding the
pathophysiology of tuberculosis for several reasons:18 First, it the most abundant component
of the organism. Second, it is the largest lipid known. Non-pathogenic mycobacteria have
smaller and less toxic species of TDM. Third, its two sets of surface-dependent activities are
unique in biology. Finally, since MTB is an obligate human parasite, it is safe to assume that
every component of MTB has been selected to facilitate its survival in man. Virulent MTB
expend great energy to produce far more TDM during infection than is required for survival
in artificial culture. Much of the TDM is released outside the organism where it directly
interacts with the host. The benefit to the organism must be worth the expenditure of
resources.
These studies have progressively come together to suggest answers to long standing
mysteries of tuberculosis. The ability of TDM to switch between two vastly different sets of
biologic activities is essential. While TDM remains on organisms, it protects them from
killing by macrophages. Once it comes off the organisms and associates with lipid, TDM
becomes the driver of caseation necrosis.19 This led to correction of long standing
misconceptions of the pathology of adult pulmonary tuberculosis, to development of
prototype drugs that overcome natural resistance of MTB to antibiotics, and to vaccines that
counter MTB’s ability to suppress immunization. Each of these findings will be
described.20–22
3. Effects of TDM on colony morphology
We published evidence confirming the hypothesis that TDM causes cording of
mycobacteria.23 TDM is released free by organisms but is so insoluble that much remains
stuck to them. MTB grown in liquid medium without surfactants preferentially grows
floating on the surface as a pellicle. The pellicle of virulent organisms spreads rapidly across
the surface as a thin film and friable climbs the sides of the container, Fig. 2. Avirulent
organisms tend to grow as discrete clumps. We demonstrated that this spreading climbing
pellicle growth of virulent MTB is due to TDM that forms a monolayer and then multilayers
on the surface of the media.23 The rigidity of TDM layers causes the pellicle of virulent
MTB to spread and climb the walls of a container.
We observed that organisms isolated from pulmonary cavities typically grow more rapidly
and produce more TDM than organisms of the same clade isolated from non-pulmonary
sites.24 These growth patterns could be demonstrated only with fresh clinical isolates. Once
the organisms were passaged in culture, the growth patterns changed. This implies that MTB
frequently grow rapidly and produce large amounts of TDM in a cavity while they grow
much more slowly producing less TDM in other organs. These observations are consistent
with the observations that very little TDM is required to protect MTB in macrophages and
that MTB appear to grow as pellicles on the walls of cavities. We proposed that large
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amounts of the TDM in the toxic monolayer configuration are required for maintenance of
cavities.18
4. New drugs directed at natural resistance of MTB to antibiotics
MTB can display at least three different types of resistance to antibiotics. The first and most
familiar is genetic resistance in which mutations produce resistance to particular drugs. The
second, phenotypic resistance, occurs when MTB become dormant making them refractory
to agents that inhibit active metabolic processes. Finally, natural resistance consists of
barriers and efflux pumps that retard penetration of antibiotics into organisms.25 Many
investigations are scrutinizing the metabolic pathways of MTB in an effort to identify new
targets for antibiotics to combat genetic and phenotypic resistance. However, very little
attention has ever been paid to the possibility of overcoming natural resistance.
Since natural resistance of MTB has been related to lipid barriers, we proposed that surface-
active agents that disrupt surface lipids of MTB might facilitate penetration of antibiotics.
Following the lead of D’Arcy Hart that certain surfactants could potentiate the activity of
antibiotics against MTB, we conducted structure–activity studies that identified a poloxamer
surfactant, CRL-1072, as an optimal agent that caused drug-resistant MTB to become
susceptible to therapeutic serum levels of several antibiotics.21,26 In the presence of
CRL-1072, drug-resistant MTB were rendered highly sensitive to both first and second line
antibiotics. The greatest effect was observed with two drug-resistant strains in which
CRL-1072 completely restored susceptibility to first line drugs, INH and rifampin.
CRL-1072 reduced the MIC of one strain 66-fold from 10 μg/mL to 0.15 μg/mL and the
other nearly as much from 10 μg/mL to 0.2 μg/mL.
CRL-1072 significantly enhanced the activity of INH, rifampin, streptomycin, pyrazinamide
and ethambutol on acute tuberculosis in mice, Fig. 3. These studies progressed to the point
of filing an IND that was approved for phase I studies in 1996. However, at that time MDR
MTB in New York was being controlled by DOTS and no one was interested in pursuing
new drugs for a small and shrinking market. Subsequently, WHO evaluated worldwide
R&D for drugs against MTB to identify a shortlist for development.27 CRL-1072 was on the
shortlist with the recommendation to “pursue further with a view to encouraging further
efficacy and toxicity studies”. With the continuing resurgence of multidrug-resistant
tuberculosis and paucity of new drug candidates, we believe that agents, like CRL-1072, that
overcome natural resistance to tuberculosis deserve reconsideration.
4.1. Drugs effective against MTB in cavities
MTB in cavities are particularly difficult to eradicate with antibiotics and are the primary
site of generation of new antibiotic-resistant strains. MTB in cavities characteristically grow
on the air–tissue surface as pellicles.28,29 The pellicle of MTB is a type of biofilm, and
bacteria, including mycobacteria, in biofilms have increased resistance to antibiotics.23,30
We have shown that non-toxic surfactants can disrupt pellicles of MTB and either kill the
organisms or make them more susceptible to antibiotics.
5. Biologic activities of TDM on MTB organisms
The most unusual property of TDM is that its biologic activity changes with its
conformation from non-toxic micelles to a highly toxic monolayer.11–14 While the structure
of TDM on MTB is not completely characterized, it does consist, at least in part, of micelles.
While non toxic, micelles are not inactive. It has been known since the 1950’s that removal
of TDM from the surface of MTB reduces their ability to survive in mice.31,32 The
experimental model of extracting surface lipids from viable organisms with wet petroleum
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ether and reconstituting them with purified TDM has proved highly informative for studies
of the mechanisms of these activities. Jessica Indrigo demonstrated that removal of lipids
from the surface of MTB caused over 99% of organisms to be killed in macrophages in
tissue culture within three days, Fig. 4.33,34 Reconstituting the organisms with purified TDM
restored their ability to survive in macrophages almost completely. Surprisingly, MTB
produced far more TDM than was required to restore their protection within macrophages.
Reconstitution of MTB with less than 10% of the TDM removed was sufficient to
completely restore protection of the organisms within macrophages. Since MTB is an
obligate human pathogen and TDM synthesis is energy intensive, this implies that TDM has
additional functions that are necessary for survival of MTB in humans.
Further studies revealed that TDM on mycobacteria inhibited phagosome–lysosome fusion
and acidification of phagosomes.33,34 Recent studies have demonstrated that TDM on MTB
also inhibits the ability of MTB to present antigens to T cells, thereby preventing the
induction of strong immune responses.35 TDM even inhibits the ability of interferon gamma
to enhance antigen presentation. Celestine Kan demonstrated that interaction of TDM with
toll-like receptors induces Suppressors Of Cytokine Signaling (SOCS-1 and SOCS-3) by
TDM on MTB. SOCS-1 and SOCS-3 then inhibit antigen presentation and induction of T
cell immunity.
Dr Jagannath recently used these concepts to produce an improved vaccine for
tuberculosis.22 Many attempts have been made to improve BCG by incorporating additional
antigens to induce stronger immune responses. However, the organisms’ evasive
mechanisms prevented the development of optimal immune responses. Our work suggested
two means to neutralize BCG’s evasive mechanisms. The first was to reduce MTB’s ability
to synthesize TDM. The final step in synthesis of TDM is mediated by a mycolyl transferase
enzyme, Antigen 85a. Deletion of the gene, fpbA, that encodes for Antigen 85a produces an
organism deficient in TDM production.36 Dr. Jagannath demonstrated that this organism is
more immunogenic than the wild-type BCG.37 He then hypothesized that a drug, rapamycin,
that modulates the movement of particles in cells, would cause mycobacterial antigens to
more effectively enter pathways leading to immunization. Immunization with this dual-
approach vaccine produced a tenfold increase in the number of organisms killed and a
threefold increase in the duration of protection. These findings “break new ground in
vaccine research in general and make improvements for antiTB vaccines in particular,
because they provide a simple and powerful strategy to enhance vaccine efficiency”.22
In other studies, Hwang and Actor used a novel lactoferrin adjuvant with BCG to produce a
vaccine that reduced the chronic pathologic response to MTB.38 This vaccine caused
reduction of the lipid pneumonia of progressive tuberculosis that we believe is a valuable
model of postprimary tuberculosis in humans. This pathology in mice, like human
postprimary tuberculosis, develops preferentially in individuals with sufficient immunity to
control primary tuberculosis. The facts that no vaccine has ever shown efficacy against
postprimary tuberculosis and that young immunocompetent people with strong tuberculin
skin tests are the most likely to die rapidly from postprimary tuberculosis have led some to
question the ability of the immune system to control this form of tuberculosis. To our
knowledge, this is the first vaccination study in animals to suggest that that it may be
possible to produce a vaccine against postprimary tuberculosis.
5.1. TDM causes caseation necrosis
If tightly clumped cords of virulent MTB come in contact with droplets of oil, the organisms
enter the oil drop and become dispersed.2 When this happens, TDM, being a surface-active
agent, comes off the organisms and forms a monolayer on the surface of the oil. In this
configuration, it exhibits an entirely different set of biologic activities. For many years, the
Hunter et al. Page 5
Tuberculosis (Edinb). Author manuscript; available in PMC 2013 June 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
toxicity of TDM on oil was considered unphysiologic because mineral oil is not a normal
constituent of the body.7 However, increasing evidence demonstrates that this is exactly how
it works to produce caseation necrosis in tuberculosis.18 Oil is provided by lipids in the body
and the combination of TDM with lipid appears to be central to the pathogenesis of
tuberculosis.
5.2. Macrophage toxicity
The toxic monolayer of TDM forms spontaneously at water–hydrophobe interfaces
including oil, polystyrene and air. Human or mouse macrophages adhere to polystyrene
tissue culture dishes and spread as pseudopods within a period of hours. If a dish is coated
with a single molecular monolayer of TDM, the macrophages spread in minutes in 360
degrees of arc without forming pseudopods.18 Many are killed within minutes by a process
of membrane blebbing that resembles oncosis.39 If TDM is spread as a molecular monolayer
on hydrophobic beads, the beads are rapidly taken up by macrophages. The subsequent
effects depends upon the size of the beads. Small beads are less toxic.40 Larger beads are
taken into phagosomes. A short time later tight adherence is observed between the
phagosomal membrane and the bead, resulting in disruption of the membrane and death of
the macrophages.41 It may be that macrophage membranes can withstand rapid adhesion and
spreading on a small surface, but are torn apart by such spreading on large surfaces.
5.3. Nonallergic, and allergic granulomas
If TDM is injected intravenously into mice as oil emulsion or coated on beads, it induces
activated foreign body granulomas in the lung.42,43 These granulomatous responses are
associated with production of TNF and other cytokines,44–46 as well as complement
factors.47–49 TDM also produces local inhibition of corticosteroid activity that could be a
factor in developing tuberculosis.50 The granulomas heal over a period of weeks. Injection
of TDM into immune animals produces very different effects. Animals can be immunized
with BCG, chronic MTB infection or with TDM complexed with methylated BSA, but not
by TDM alone. In appropriately immunized animals, TDM produces hypersensitivity
granulomas.51–53 These are larger granulomas cuffed by a rim of lymphocytes with more
activated appearing macrophages and necrosis at their centers. Immunization to produce
such granulomas requires CD1-mediated antigen presentation for full development of an
immune response.53 The effector cells are CD3+ CD4+ positive T cells since ability to
produce hypersensitivity granulomas can only be transferred from animal to animal by these
cells, but not by macrophages, CD8 or CD19 positive cells.52
5.4. Caseating granulomas in mice
The literature for many decades has reported that mice are a flawed model of tuberculosis
because they fail to produce caseating granulomas following infection with a low dose of
MTB. However, a TDM–mineral oil emulsion, injected intraperitoneally into mice with
chronic tuberculosis, induced classic caseating granulomas.19 A series of experiments were
conducted to characterize these lesions. Variations in protocols produced a series of
caseating granulomas each of which resembled a particular phase of human disease. They
could be induced either by a TDM emulsion or by a dose of virulent MTB containing
sufficient TDM. Typical caseating granulomas were produced in the lung, pancreas,
mediastinum and mesentery. Caseating granulomas in the lung formed in adipose tissue
unless the MTB were injected with oil in which case they formed in association with the oil
in lung parenchyma. Those in the mesentery closely resembled human mesenteric
tuberculosis in that they were located in adipose tissue densely infiltrated with lymphocytes
with central caseation necrosis and Langhans-type giant cells.18 Early in the formation of
such lesions, acid fast bacilli could be found within fat cells demonstrating that association
of TDM with lipid droplets could happen during infections. Other protocols produced
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caseating granulomas which persisted for months containing large numbers of acid fast
organisms after the bacteria had been largely cleared from other parts of the body, Fig. 5.
These lesions were encapsulated by dense fibrosis tissue in a pattern characteristic of
chronic lesions in humans.
5.5. Caseating granulomas in humans
The observation that mice can produce a spectrum of typical caseating granulomas
stimulated investigations of how they form in mice and the relevance of these findings for
tuberculosis in humans. It has long been known that caseation necrosis in humans is largely
lipid of host origin.28 Active caseating granulomas in humans characteristically contain
prominent lipid droplets in association with epithelioid cells. This was true of all specimens
we examined, including brain, bone, liver, lung, lymph node and kidney. In addition,
caseating granulomas stained strongly for fat.54 In mice, caseating granulomas formed by
association of MTB or purified TDM with lipid. We were able to distinguish two patterns of
necrosis: caseation and ischemic.19 TDM alone produced only the caseation while MTB
produced both. Evaluation of microscopic sections of human tuberculosis demonstrated that
caseating granulomas in humans also display evidence of both caseation and ischemic
necrosis. It was even possible to demonstrate acid fast organisms within lipid droplets and
fat cells in newly forming human caseating granulomas, Fig. 6. Collectively, these data
demonstrated that mice can produce a spectrum of caseating granulomas each of which
reproduces a particular manifestation of human tuberculosis.19
6. Pathology of postprimary tuberculosis
Modern science has produced powerful tools for dissecting molecular and cellular
mechanisms of disease. However, even the best tools require appropriate targets. The choice
of molecular targets for study of a disease depends on understanding cell biology and tissue
pathology. It seems incomprehensible, but it is true, that the contemporary scientific
literature could completely fail to understand the basic pathology of postprimary
tuberculosis and, as a result, be unable to approach long standing questions. This situation
developed as follows:
Postprimary tuberculosis occurs preferentially in people with sufficient immunity to resolve
primary tuberculosis. It is a different disease from primary tuberculosis on clinical,
radiologic, immunologic, epidemiologic, pathologic and genetic grounds.20 Postprimary
tuberculosis is responsible for 80% of clinical disease and nearly 100% of transmission from
person to person. Typically an upper lobe of lung becomes infected, undergoes necrosis and
develops a cavity while the entire rest of the body remains highly immune. Immunization
with BCG effectively prevents dissemination of primary tuberculosis, but has never been
shown to have any effect on postprimary tuberculosis. Unfortunately, postprimary
tuberculosis is strictly a human disease. Several animals develop progressive primary
tuberculosis, but none develop postprimary disease. We know a great deal about primary
tuberculosis, but without animal models, postprimary tuberculosis has remained largely
unapproachable by modern science. Most of the major unresolved questions of tuberculosis
involve postprimary disease. Why is it restricted to the lung? How does it produce tissue
damage? Why don’t cavities heal? Why doesn’t immunity heal cavities or prevent their
development? Why is strong immunity detrimental in that young immunocompetent adults
are the most likely to die?55 The inability of immunity to control postprimary tuberculosis
has never been explained.
The pathologies of both primary and postprimary tuberculosis were clearly described by the
end of the 19th century.56 The advent of antibiotics in the 1950’s produced a sharp drop in
lung tissues for study of postprimary tuberculosis and diminution of interest in the disease.
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The few researchers remaining were forced to study animal models, particularly the rabbit.57
Unfortunately, rabbits are resistant to MTB, but they are susceptible to M. bovis, the
organism that causes tuberculosis in cattle. Many new facts about macrophages, granulomas
and immunity were learned from studies of M. bovis. However, the older descriptions of
pathology were forgotten. Consequently, virtually all modern descriptions of the
pathogenesis of postprimary tuberculosis are descriptions of M. bovis infection of rabbits.
Postprimary tuberculosis is almost universally described today as an accelerated primary
tuberculosis in which caseating granulomas progressively enlarge, erode into bronchi,
undergo softening and discharge their contents to leave a cavity. This pathologic process has
been reported in humans infected with M. bovis, but has never been reported and probably
never happens in people infected with MTB.58
Our finding of caseating granulomas in mice stimulated search for literature and pathologic
specimens of postprimary tuberculosis. We collected histopathologic slides from over 100
autopsy cases of primary and postprimary tuberculosis and reviewed the extensive literature
from the preantibiotic era. This was made possible because Google Books can search old
libraries almost as well as current literature. Modern textbooks provide an accurate
description of the development of cavities in progressive primary tuberculosis in rabbits.
Human postprimary tuberculosis, however, develops through a different pathologic process
that is nowhere found in contemporary literature.20
Postprimary tuberculosis occurs as an endogenous lipid pneumonia in people with sufficient
immunity to control primary tuberculosis and heal caseating granulomas, Fig. 7. Infection is
restricted to alveolar macrophages and may cause little inflammation in the early stages. It is
occasionally diagnosed by finding X-ray evidence of upper lobe pneumonia in people who
are not sick. Postprimary tuberculosis begins in the upper lobes of the lung and progresses
slowly for about a year before rapidly undergoing necrosis to produce a cavity.20,28 The
lungs characteristically develop caseous pneumonia that develops from lipid pneumonia, not
from granulomas. Cavities typically develop in lungs with no granulomas. Granulomas and
caseating granulomas are characteristic lesions of primary tuberculosis. Lipid pneumonia is
the characteristic lesion of postprimary tuberculosis. A consequence of the failure to
understand the pathology of postprimary tuberculosis is that the most important and
troublesome lesions of tuberculosis lie largely beyond the reach of modern science.
Postprimary tuberculosis resolves spontaneously in approximately 90% of people prior to
development of cavities. Once cavities develop, however, they almost never heal
spontaneously. Almost nothing is known of the factors that determine whether postprimary
tuberculosis resolves or progresses to cavitation. Chronic cavitary tuberculosis is a complex
process that can assume multiple histopathologic forms.28
The recognition that postprimary tuberculosis begins as a lipid pneumonia immediately
suggests models and hypotheses to study it further. Available data identifies at least two
factors that contribute to development of tuberculous lipid pneumonia. The first is bronchial
obstruction that occurs in 100% of cases of early postprimary tuberculosis.59 In its early
stages, tuberculous pneumonia closely resembles post obstructive or golden pneumonia that
occurs distal to bronchial obstructions and probably nerve damage by cancer.56,60 We have
found such cases with large cavities resulting from coagulation necrosis of lipid pneumonia
remarkably similar to caseation and cavities of tuberculosis. This suggests that bronchial
obstruction and nerve damage may contribute to cavity formation in tuberculosis. Second,
mycolic acids cause macrophages, especially alveolar macrophages, to accumulate lipid and
become tolerant to ingested mycobacteria.61 Much more study is needed.
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Chronic slowly progressive tuberculosis in the mouse has been criticized as a model of
human tuberculosis because it does not produce caseating granulomas.62 However, it is a
progressive lipid pneumonia with many similarities to the human disease. We proposed,
therefore, that it is an excellent model of early postprimary tuberculosis.20
7. The role of TDM in formation and maintenance of cavities
While much remains unknown, available data support the hypothesis that the monolayer
form of TDM is a major factor in both the pathogenesis and maintenance of cavities. In most
mouse and human studies, lipid progressively accumulates in endogenous lipid pneumonia
over a period of months before the lesions rapidly undergo necrosis.19,62 In murine studies,
mycobacterial components have been shown to accumulate with host lipids.63 Our
hypothesis is that conditions eventually develop for activating the toxicity of the TDM by
interaction with lipid droplets. Once activated, the toxicity of TDM increases several orders
of magnitude and it becomes highly immunogenic leading to the rapid necrosis and cavity
formation. We have found that injections of TDM in the toxic form accelerate development
of necrosis of murine tuberculous lipid pneumonia.
As described above, MTB isolated from cavities typically grow much faster and produce
much more TDM than those isolated from other organs. Since MTB can only be efficiently
transmitted to new hosts from cavities in the lung, rapid growth of organisms in any other
part of the body is likely to kill the host and the organisms as well. Consequently, cavities
are the only place where MTB benefits from rapid multiplication. The production of large
amounts of TDM by organisms in cavities suggest that TDM is essential for the maintenance
of cavities. Laennec observed long ago that a smooth velvety layer lines mature cavities.64
Histologically, this layer is a mass of organisms resembling a pellicle.18 Consequently, it
seems that spreading, climbing behavior of pellicles in culture reproduces their behavior in a
cavity. This is also consistent with Indrigo and Actor’s observation that the amount of TDM
on the surface of organisms is far more than is required to prevent their killing by
macrophages.33,34
8. Conclusion
In summary, many fundamental questions of the pathogenesis of tuberculosis have remained
out of reach of modern science because of lack of informative models. By focusing on
TDM, our studies have developed several new models, new understanding of the disease and
new approaches to combat it. We began with decades-old evidence that TDM is necessary
for virulence of MTB. Continuing studies demonstrate that TDM is truly unique. Neither
micellar nor monolayer TDM conforms to paradigms of modern biology. There is no other
known biologic substance that has similar properties or activities. By changing
conformation, TDM can switch between two very different sets of biologic activities. While
surface-dependent toxicity is well established for certain mineral crystals, it is unique among
biologic substances. On organisms, TDM is non toxic and protects the organisms from host
defenses by several mechanisms. If it comes off organisms and associates with lipid, TDM
becomes the most toxic, immunogenic and destructive component of the organism. MTB is
an obligate human parasite. It can infect other species, but is transmitted only by people.
Since virulent MTB expend large amounts of energy synthesizing far more TDM in our
lungs than they need to survive in culture, it is safe to assume that it TDM is necessary for
its survival as an infectious agent. We propose that understanding the activities of the two
conformations of TDM is the key to unraveling several of the most perplexing mysteries of
tuberculosis.
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Fig. 1.
Toxic monolayer and non-toxic micelle structures of TDM.13 TDM molecules consist of one
trehalose attached to two mycolic acid moieties each of which has a short and long
hydrocarbon chain. In aqueous suspension, TDM forms non-toxic cylindrical micelles as
shown in a diagram and by scanning tunneling microscopy at 500,000× magnification (left-
hand panel). The surface consists entirely of trehalose moieties with the fatty acid chains on
the inside. These micelles are non toxic, but have important functions on MTB. TDM forms
a toxic crystalline monolayer at hydrophobe–aqueous interfaces as shown in a diagram and
by scanning tunneling microscopy at 1,840,000× magnification (right-hand panel). The
major dark lines, spaced approximately 90 Å, are elevated arrays of trehalose head groups.
A secondary pattern intersecting the main one at an angle of 45° has a periodicity
approximating 65 Å and represents the mycolic acid residues. Susceptible mice are killed by
as little as 10 μg of TDM in this configuration.
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Fig. 2.
Pellicle cultures of MTB.23 Attenuated MTB form easily crumbled aggregates with no
tendency to spread. Fragments could be easily broken off without disturbing the rest of the
surface. Virulent MTB typically form pellicles that spread and climb the walls of flasks. The
pellicle surface has multiple holes that give it an appearance resembling lace. Touching any
part of this pellicle causes the entire surface to move. The spreading, climbing behavior of
the pellicle is due to excess TDM.
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Fig. 3.
Overcoming natural resistance of MTB to antibiotics.21 The combination of CRL-1072 with
each drug reduced CFUs in lungs below the levels achieved by the drug alone. The
combinations of CRL-1072 with isoniazid (INH), rifampin (RIF), streptomycin (SM) and
pyrazinamide (PZA) produced significant bactericidal effects while the antibiotic alone was
only mildly bacteriostatic. Ethambutol (ETH) had a significant bacteriostatic effect. Top
horizontal line = 28 day growth in untreated controls. The lower horizontal line = CFU
counts at day 0 baseline.
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Fig. 4.
TDM protects MTB from killing by macrophages.33 J774A.1 macrophages were infected
with native MTB, delipidated MTB (delipid. MTB) or delipidated MTB reconstituted with
TDM (delipid. MTB + TDM), m.o.i. 5:1. Mycobacterial survival was measured by colony-
forming units (CFU) at 4, 24, and 72 hours after infection. Data are expressed as average
log10 CFU ± one SD, 3 replicates per time point. 99% reduction in CFU of delipid. MTB
occurred by 72 hours (P < 0.025). TDM reconstitution protected the MTB almost
completely.
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Fig. 5.
Persistent caseating granuloma in a mouse.19 This mouse was injected i.p. with 100 μg
TDM in an oil-in-water emulsion and with 106 MTB i.v. one day later. The lesions were
examined after 80 days. The large section (right-hand panel) shows an encapsulated lesion
consisting of dense connective tissue, fibroblasts and macrophages surrounding caseation
necrosis with focal calcification (Trichrome connective tissue stain, 20× magnification).
Upper left section shows a thin layer of foamy macrophages between the capsule and
interior caseous necrotic material (H&E stain, 400× magnification). Lower left section
shows that many more MTB were present in this lesion than in any other part of the body
(AFB stain, 1000×).
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Fig. 6.
Interaction of MTB with lipid in developing human caseation necrosis.18 AFB in lipid
droplets of foci of developing necrosis in the lung of a human with postprimary tuberculosis
(AFB stain 1000×) (left). These sections demonstrate that MTB associates with lipid in foci
of developing necrosis of tuberculosis. TDM remains with MTB until it encounters a lipid
interface. It then comes off the organisms and assumes a stable monolayer configuration on
the interface thereby activating its toxicity and antigenicity. The diagram (right) shows MTB
transferring TDM to the surface of an oil drop. Observation of this phenomenon led Bloch to
discovery of cord factor.2 Gentle extraction with oily solvents is still used to purify TDM
and to produce delipidated organisms that have reduced virulence.
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Fig. 7.
Histopathology of postprimary tuberculosis.20 This section is from a person who died
suddenly of hemoptysis. Autopsy revealed tuberculosis in the upper lobes of both lungs with
early cavitation that caused massive bleeding. The section illustrates the typical pathology of
developing postprimary tuberculosis (H&E, 200×). It is an endogenous lipid pneumonia.
The alveoli are filled with foamy macrophages, fibrin, and cell debris. Alveolar walls are
infiltrated by lymphocytes. No granulomas were present anywhere in these lungs. MTB
were present only in alveoli associated with alveolar macrophages and debris (insert; 1000×
acid fast stain).
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